Tag: tissue

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978

The Canadian Food Inspection Agency implements disease control measures to prevent spread of New World Screwworm

OTTAWA, ON, June 5, 2026 /CNW/ - Following a confirmed finding of New World screwworm in a calf in Texas, the Canadian Food Inspection...

“Premium Pet Supplies Expo 2026” Officially Opens

Exotic Pets Steal the Spotlight with Debut Reptilia Carnival and Live Insect Exhibition Featuring Over 50 SpeciesHONG KONG, June 5, 2026 /PRNewswire/ -- Organized...

Gift of Life Marrow Registry Gala Celebrates First-Time Meetings Between Two Transplant Recipients and Their Lifesaving Donors

Gift of Life Marrow Registry hosted its annual NYC Gala, where two transplant recipients, including a 13-year-old boy, were united with their donors.

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors....

MISOORA Unveils Revolutionary K-Beauty Skincare Range Emphasizing Longevity Over Anti-Aging

A five-step biotech regimen, anchored by NAD+ and Retinaldehyde, opens its founding waitlist ahead of a June 22 US debut.

A five-step biotech regimen, anchored by NAD+ and Retinaldehyde, opens its founding waitlist ahead of a June 22 US debut.

Aphranel® Marks First Anniversary with EU MDR Certification, Arc™ Launch, and Over 150,000 Syringes Delivered

SHANGHAI, June 5, 2026 /PRNewswire/ -- On May 20, 2026, Aphranel® celebrated its first anniversary at the Waldorf Astoria Shanghai on the Bund, marking a...

Mabwell’s 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease

SHANGHAI, June 4, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently developed innovative...

London Specialist Dentists Announce the Use of Ozone Therapy in Periodontal Treatment and Dental Implants

LONDON, June 04, 2026 (GLOBE NEWSWIRE) -- London Specialist Dentists has announced the use of medical-grade Ozone Therapy as part of its advanced approach to periodontal treatment, dental implant care, and minimally invasive gum therapy.

Mammotome Expands Access to Innovative Breast Biopsy Site Marker

Securing this CE mark expands access to the HydroMARK™ Plus markers across Europe, combining proprietary hydrogel technology with features designed to support marker stability...

AbolerIS Pharma Presents New Data Supporting CD45RC as a Novel Therapeutic Target and Potential Biomarker in Sjögren’s Disease at EULAR 2026

- Findings demonstrate strong correlation between CD45RC expression and lymphocytic infiltration in salivary glands, supporting its potential as both an early biomarker and therapeutic...

Gujarat becomes the New Hub in Organ Transplantation

Zydus Hospitals Ahmedabad and Vadodara reach new heights in advanced transplant care AHMEDABAD, India, June 4, 2026 /PRNewswire/ -- Organ transplantation in India has come a...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsTissue

Chandigarh University holds 8th CU Online Annual Convocation; 363 Students Degrees Awarded

Fox ESS Unveils Dynamic Energy Ecosystem Alongside Its First Rebrand Area at SNEC 2026

Deepak Group Goes Beyond Green with hands-On Mangrove Restoration